Mylan Pharmaceuticals Under Federal Scrutiny

For the fourth month in a row pharmaceutical companies have made scandal headlines and January came with a repeat offender, Mylan Pharmaceuticals. Just months after a $456 million dollar fraud settlement with the DOJ Mylan is being investigated for violating antitrust laws, which ensure that fair competition between companies. [1] The company’s practices were first questioned back in September, a month before the settlement was completed, by New York Attorney General Eric Schneiderman. On January 30th Mylan admitted that federal antitrust regulators have in fact launched an investigation, one which has reportedly been ongoing for months. [2] As with the settlement case, Mylan representatives still assert that all accusations are “without merit.” [3] Mylan continued to state that “the epinephrine auto-injector market is and always has been competitive, with multiple products competing on the market since we acquired EpiPen Auto-Injector.” [3]

References:

1. Emily Willingham, “EpiPen Maker Mylan Agrees to $465 Million Settlement with DOJ,” last modified October 7, 2016, http://www.forbes.com/sites/emilywillingham/2016/10/07/epipen-maker-mylan-agrees-to-465-million-settlement-with-doj/#455ec3ccc921

2. Dan Mangan, “Mylan face federal antitrust investigation in EpiPen business,” last modified January 30, 2017,  http://www.cnbc.com/2017/01/30/mylan-faces-federal-antitrust-investigation-in-epipen-business.html

3. Anya Tharakan, “Mylan says being investigated over EpiPen practices,” last modified January 30, 2017, http://www.reuters.com/article/us-mylan-nl-epipen-probe-idUSKBN15E2NY

New Form of Male Contraception Shown to be Effective in Monkeys

New Form of Male Contraception Shown to be Effective in Monkeys

Doctors Without Borders Turns Down Donation of One Million Vaccines

Doctors Without Borders Turns Down Donation of One Million Vaccines

0